Martin Haluzík

Mar 17, 2025 | dom-pubs.onlinelibrary.wiley.com | Martin Haluzík |Katarzyna Cypryk |Agustina Alvarez |Felipe Lauand

1 INTRODUCTION Due to the progressive loss of β-cell function in type 2 diabetes (T2D), advancement to injectable therapy may be required to control hyperglycaemia.1 The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) state that the fixed-ratio combination therapy (FRC) of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and basal insulin has potent glucose-lowering action and recommends FRCs when treatment targets are not met with either...